Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotiraciclib (TG02) Plus Temozolomide in Recurrent Anaplastic Astrocytoma and Glioblastoma
NCT02942264Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zotiraciclib in anaplastic astrocytoma (AA), glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started Dec 2016; status: terminated.
02
Drugs
zotiraciclib
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02942264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942264.